FLASH NOTE

India | Financial Services | 28-January-2015

Max India - Demerger

Value accretive but already priced in

Max India on 27 Jan 2015 announced a corporate restructuring plan to split the company into three separate units — Max Financial Services, Max India, and Max Ventures and Industries. We view this as a positive for existing shareholders given the conglomerate discount will be done away with and investors will have access to a pure listed Life Insurance firm. Max Financial Services will be the first pure listed life insurance play in India and will provide a valuation benchmark in the Indian life insurance sector. The open offer in the speciality films business is also a positive as it will provide an exit opportunity for investors not interested in that entity. However, we believe the benefits of corporate restructuring are more or less priced in and hence see limited upside from the current levels.

Max India corporate restructuring is value accretive for shareholders

Max India's board has approved a corporate restructuring plan to vertically split the company through a demerger into three listed companies (refer Figure 1 on page 2 for details on the corporate structure):

- (a) Max Financial Services: The existing company will be renamed Max Financial Services and will hold a 72.2% stake in Max Life Insurance.
- (b) **Max India** (resulting Company 1): It will house Max Bupa, Max Healthcare, and Antara Senior Living businesses and will be called Max India Limited.
- (c) Max Ventures and Industries: The third company will be called Max Ventures and Industries (resulting Company 2) and will house the Speciality films business.

The restructuring in our view is value accretive for investors' point of view as:

- a) Conglomerate discount will vanish: Analysts' in general assign 10%-20% holding company discount to the company, which now will be done away with in the new corporate structure as the two companies will be pure play companies. However, Max India (resulting Company 1) could continue to be valued with a holding company discount.
- b) Allays concerns on capital allocation: Investors' had concerns on capital allocation, cash utilization and dividend payment by the company. Post the demerger, Max Life's dividend will be attributed to Max Financial Services shareholders only.
- c) Offers opportunity for a pure play life insurance: Max Financial services would be the first listed pure play in the Indian life insurance sector. We have been upbeat on the potential of the sector and Max Life has been our top pick in the space.
- d) Open offer from promoter will floor the valuation of specialty films business: The promoter has announced an open offer to increases its stake to 75% valuing the company at enterprise value of INR 4,680 m at 6.0xFY16E EBITDA.

Corporate restructuring benefits priced-in

Max India (MAX IN, BUY, FV: INR500) has rallied 23% in the last five trading sessions. In our view, this rally has priced in benefits of corporate restructuring and hence we see limited upside potential in the stock at current valuation.



| BUY | 2% upside |
|-----------------------|---------------|
| Fair Value | Rs500.00 |
| Bloomberg ticker | MAX IN |
| Share Price | Rs492.00 |
| Market Capitalisation | Rs130,841.00m |

65%

| INR m Y/E 31-Mar | 2013A | 2014A | 2015E | 2016E |
|-----------------------|---------|---------|---------|---------|
| Revenues | 106,236 | 116,832 | 120,735 | 133,488 |
| Operating Expenditure | 94,110 | 111,777 | 115,000 | 125,799 |
| EBITDA | 12,126 | 5,056 | 5,735 | 7,689 |
| PBT | 9,914 | 2,744 | 3,432 | 5,329 |
| PAT after MI | 7,841 | 1,394 | 2,141 | 3,197 |
| EPS | 29.4 | 5.2 | 8.0 | 12.0 |
| EVPS | 141.0 | 148.4 | 160.6 | 175.7 |

Exceptional gain of Rs8022mn in 2013 on account of stake sell in Life Insurance

| Y/E 31-Mar | 2013A | 2014A | 2015E | 2016E |
|------------------------|-------|-------|-------|-------|
| RoEV (Max Life) | 10% | 13% | 17% | 19% |
| NBAP Margin (Max Life) | 13.6% | 13.1% | 11.5% | 13.0% |
| P/EV (Max Life) | 3.5 | 3.3 | 2.8 | 2.4 |
| P/E | 16.7 | 94.0 | 61.2 | 41.0 |
| P/B | 4.5 | 4.4 | 4.3 | 4.2 |
| Debt/Equity | 0.3 | 0.3 | 0.3 | 0.3 |
| RoA | 3.7% | 0.6% | 0.7% | 1.0% |
| RoE | 29% | 5% | 7% | 10% |




Source: BESI Research, Company Data, Bloomberg

Analysts

Nidhesh Jain, CFA +91 22 4315 6823 nidhesh,jain@espiritosantoib.co.in Espirito Santo Securities India Private Limited

Figure 1 Revised Corporate structure of Max India - Total combined valuation = INR 130 bn along with total cash of INR 6 bn



Source: BESI Research, Company Data

Valuation Methodology

We have valued the company on a sum of the parts basis. We value the Life Insurance entity using the Appraisal Value Method with FY16 as the base year for embedded value. We have used a NBAP multiple of 22x. Max Healthcare is valued using discounted cash flow methodology with 10 years of explicit forecast, terminal growth rate of 8% and cost of equity of 12%. Max Bupa is valued at 1.8x capital infused basis and Max Specialty films is valued 8x FY16E EBITDA

Table 1 Max India - Sum of the parts

| Business Segment | Valuation | Max India Stake | Value per share | Methodology |
|------------------|-----------|--------------------|--------------------|--|
| Life Insurance | 137,759 | 72% | 373 | Appraisal Value Method (FY16E EV + 22x FY16 NBAP) |
| Max Healthcare | 23,971 | 66% | 59 | Discounted Cash Flow |
| Max Bupa | 12,492 | 74% | 35 | 1.8x Value of Capital Infused |
| Specialty Films | 8,640 | 100% | 32 | EV/EBIDTA Multiple (8x FY16 EBIDTA) |

| Total SOTP Valuation Soc | Total SOTP Valuation | 500 | |
|--------------------------|----------------------|-----|--|
|--------------------------|----------------------|-----|--|

Source: ESS Research, Company Data

Risks to Fair Value

We believe the regulatory overhang is over for the Life Insurance sector, and any further regulatory intervention will be a risk to our fair value. Moreover, we expect the loss making entities Max Healthcare and Max Bupa to break even by FY16 and FY17, respectively. Any deterioration in the operating environment of these entities that could delay the breaking even of these entities will be a risk to our consolidated profitability estimates and fair value.



| Repo | ort date | Recommendation | Fair value | Share price |
|-------|------------------------|----------------|------------|-------------|
| 2014 | November 13 | Buy | Rs500.00 | Rs438.00 |
| | June 5 | Buy | Rs405.00 | Rs326.00 |
| 2013 | May 31 | Buy | Rs308.00 | Rs218.75 |
| | May 3 | Buy | Rs307.58 | Rs216.90 |
| | April 30 | Buy | Rs279.00 | Rs213.00 |
| 2012 | August 22 | Buy | Rs279.42 | Rs181.70 |
| | April 13 | Buy | Rs279.00 | Rs204.00 |
| | February 16 | Buy | Rs252.00 | Rs188.00 |
| Sourc | e: Bloomberg, BESI Res | | | |

Please visit our website at www.EspiritoSantolB.co.uk for up to date recommendation charts.

This report was prepared by BESI Research, a global brand name for the equity research teams of Banco Espírito Santo de Investimento, S.A., with headquarters in Lisbon, Portugal, of its Branches in Spain and Poland and of its affiliates BES Securities do Brasil, S.A. – Corretora de Câmbio e Valores Mobiliários, in Brazil, Execution Noble Limited, in the United Kingdom, and Espirito Santo Securities India Private Limited, in India, all authorized to engage in securities activities according to each domestic legislation. All of these entities are included within the perimeter of the financial group controlled by Novo Banco, S.A., a Portuguese bank authorised and regulated by Banco de Portugal (Portuguese Banking Regulator) and Comissão do Mercado de Valores Mobiliários (the Portuguese Securities Market Authority), which was incorporated on the 3rd of August 2014 in the context of the resolution action taken on the former financial institution Banco Espírito Santo, S.A..

Analyst Certification

Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers; the issuers were not previously informed about the content of the recommendation included in this research report and the assumptions were not validated by the issuers; (2) no part of his or her compensation is directly or indirectly related to: (a) the specific recommendations or views expressed by that research analyst in the research report; and/or (b) any services provided or to be provided by Banco Espírito Santo de Investimento, S.A. and/or by any of its affiliates to the issuer of the securities under recommendation. Moreover, each of the analysts hereby certifies that he or she has no economic or financial interest whatsoever in the companies subject to his or her opinion and does not own or trade any securities issued by the latter.

Ratings Distribution

BESI Research hereby provides the distribution of the equity research ratings in relation to the total issuers covered and to the investment banking clients as of end of December 2014

Explanation of Rating System

| explanation of Rating System | | | | |
|------------------------------|--|--|--|--|
| 12-MONTH RA | TING DEFINITION | | | |
| BUY | Analyst expects at least 10% upside potential to fair value, which should be realized in the next 12 months | | | |
| NEUTRAL | Analyst expects upside/downside potential of between +10% and -10% to fair value, which should be realized in the next 12 months | | | |
| SELL | Analyst expects at least 10% downside potential to fair value, which should be realized in the next 12 months | | | |

| TRADING RATIN | NG DEFINITION |
|---------------|---|
| TRADING BUY | Analyst expects a positive short-term movement in the share price (max duration 3 months from the time Trading Buy is announced) and may move out of line with the fair value estimate during that period |
| TRADING SELL | Analyst expects a negative short-term movement in the |

value estimate during that period

Ratings Distribution

| As at end December 2014 | Total BESI Research | | Total Investment Banking Clients (IBC) | | |
|-------------------------|---------------------|------------|---|----------|------------|
| Recommendation | Count | % of Total | Count | % of IBC | % of Total |
| 12 Month Rating: | | | | | |
| Buy | 209 | 48.2% | 31 | 91.2% | 7.1% |
| Neutral | 142 | 32.7% | 2 | 5.9% | 0.5% |
| Sell | 80 | 18.4% | 0 | 0.0% | 0.0% |
| Restricted | 3 | 0.7% | 1 | 2.9% | 0.2% |
| Under Review | 0 | 0.0% | 0 | 0.0% | 0.0% |
| Trading Rating: | | | | | |
| Trading Buy | 0 | 0.0% | 0 | 0.0% | 0.0% |
| Trading Sell | 0 | 0.0% | 0 | 0.0% | 0.0% |
| | | | | | |
| Total recommendations | 434 | 100% | 34 | 100% | 7.8% |

For further information on Rating System please see "Definitions and distribution of ratings" on: http://www.espiritosantoib-research.com.

Share Prices

Share prices are as at the close of business on the day preceding publication, unless otherwise specified.

Sell is announced) and may move out of line with the fair

Coverage Policy

BESI Research reserves the right to choose the securities it expresses opinions on. The main criteria to choose such securities are: 1) markets in which they trade 2) market capitalisation 3) liquidity, 4) sector suitability. BESI Research has no specific policy regarding the frequency in which opinions and investment recommendations are released.

Representation to Investors

BESI Research has issued this report for information purposes only. This material constitutes "investment research" for the purposes of the Markets in Financial Instruments Directive and as such contains an objective or independent explanation of the matters contained in the material.

Any recommendations contained in this document must not be relied upon as investment advice based on the recipient's personal circumstances. This report is not, and should not be construed as an offer or a solicitation to buy or sell any securities or related financial instruments. The investment discussed or recommended in this report may be unsuitable for investors depending on their specific investment objectives and financial position. The material in this research report is general information intended for recipients who understand the risks associated with investment. It does not take account of whether an investment, course of action, or associated risks are suitable for the recipient. This research report does not purport to be comprehensive or to contain all the information on which a prospective investor may need in order to make an investment decision and the recipient of this report must make its own independent assessment and decisions regarding any securities or financial instruments mentioned herein. In the event that further clarification is required on the words or phrases used in this material, the recipient is strongly recommended to seek independent legal or financial advice. Where an investment is denominated in a currency other than the investor's currency, changes in rates of exchange may have an adverse effect on the value, price of, or income derived from the investment. Past performance is not necessarily a guide to future performance. Income from investments may fluctuate. The price or value of the investments to which this report relates, either directly, or indirectly, may fall or rise against the interest of investors. Any recommendation and opinion contained in this report may become outdated as a consequence of changes in the environment in which the issuer of the securities under analysis operates, in addition to changes in the estimates and forecasts, assumptions and valuation methodology used herein. The securities mentioned in this publication may not be eligible for sale in

All the information contained herein is based upon information available to the public and has been obtained from sources believed to be reliable. However, BESI Research does not guarantee the accuracy or completeness of the information contained in this report. The opinions expressed herein are BESI Research present opinions only, and are subject to change without prior notice. BESI Research is not under any obligation to update or keep current the information and the opinions expressed herein nor to provide the recipient with access to any additional information.

BESI Research has not entered into any agreement with the issuer relating to production of this report. BESI Research does not accept any form of liability for losses or damages which may arise from the use of this report or its contents.

This communication has been issued and approved by Execution Noble Limited in the United Kingdom where it is being directed at persons who have professional experience in matters relating to investments. It is not intended for retail customer use.

Ownership and Material Conflicts of Interest

Banco Espírito Santo de Investimento, S.A. and/or its Affiliates (including all entities within BESI Research) and/or their directors, officers and employees, may have, or have had, interests or qualified holdings on issuers mentioned in this report. Banco Espírito Santo de Investimento, S.A. and/or its Affiliates may have, or have had, business relationships with the companies mentioned in this report. However, the research analysts may not purchase or sell securities or have any interest whatsoever in companies subject to their opinion.

Banco Espírito Santo de Investimento, S.A. and/or its Affiliates do not have any qualified shareholding (1% or more) in the issuers covered in this report. Bradesco has a direct qualified shareholding (20%) in BES Investimento do Brasil, S.A., the parent company of BES Securities do Brasil S.A. CCVM.

Pursuant to Polish Ministry of Finance regulations, we inform that neither does Banco Espírito Santo de Investimento, S.A. nor its Affiliates have any qualified shareholding in the Polish Securities Issuers mentioned in this report in excess of 5% of its total share capital.

Mr. Rafael Valverde, a member of the board of Banco Espírito Santo de Investimento, S.A., is a non-executive board member of EDP Renováveis.

Banco Espírito Santo de Investimento, S.A and/or its subsidiaries are liquidity providers or market makers for Altri, Bradesco, Usiminas and Vale.

Banco Espírito Santo de Investimento, S.A. and/or its subsidiaries participate or have participated in the last 12 months as a syndicate member in share offerings of 4imprint, Alumetal, EDP, Klabin, Liberbank, Mota-Engil, Mota-Engil Africa, NAHL Group, NOS, Oi, PGE, Prime Car Management, REN, Skarbiec Holding and SKS Microfinance.

Banco Espírito Santo de Investimento, S.A. and/or its subsidiaries participate or have participated in the last 12 months as a syndicate member in the bond issues of the following companies: Abengoa, Altri, Bematech, EDP, Globe Trade Centre, Kredyt Inkaso, Mota-Engil and Sonae.

Banco Espírito Santo de Investimento, S.A. and/or its subsidiaries provided in the last 12 months investment banking services to the following companies: 4imprint, Abengoa, Altri, Alumetal, Bematech, Brazil Hospitality Group, Burford Capital, Casino Guichard, EDP, EDP Renovaveis, Galp Energia, Globe Trade Centre, Inditex, IQE, Kcom Group, Klabin, Kredyt Inkaso,

Kruk, Laird, Liberbank, Mota-Engil, Mota-Engil Africa, NAHL Group, NOS, Oi, Prime Car Management, REN, Semapa, Skarbiec Holding, SKS Microfinance, Sonae, Sonaecom, Sports Direct, SVG Capital and Ted Baker.

Affiliates of Banco Espírito Santo de Investimento, S.A. are partners to Mota-Engil in the infrastructure business in Portugal and other countries. Mota-Engil jointly with ES Concessões, S.G.P.S., S.A. (held by an Affiliate of Banco Espírito Santo de Investimento, S.A.) has created a joint holding company – Ascendi – for all stakes in transportation infrastructure concessions in Portugal and abroad. Banco Espírito Santo de Investimento, S.A. provided, or continues to provide, investment banking services to Ascendi.

Banco Espírito Santo de Investimento, S.A. and/or its subsidiaries do and seek to provide investment banking or other services to the companies referred to in this research report. As a result, investors should be aware that a conflict of interest may exist.

Market Making Uk

Execution Noble Limited is a Market Maker in companies covered and may sell to or buy from customers as principal in certain financial instruments listed or admitted to listing on the London Stock Exchange. For information on Companies to which Execution Noble Limited is a Market Maker please see "Execution Noble Limited UK Market Making" on http://www.espiritosantoib-research.com.

Confidentiality

This report cannot be reproduced, in whole or in part, in any form or by any means, without BESI Research's specific written authorization. This report is confidential and is intended solely for the designated addressee. Therefore any disclosure, replication, distribution or any action taken in reliance on it, is prohibited and unlawful. Receipt and/or review of this research report constitutes your agreement not to redistribute, retransmit, or disclose to others the contents, opinions, conclusion, or information contained in this report (including any investment recommendations, estimates or price targets without first obtaining express permission from an authorized officer of Banco Espírito Santo de Investimento, S.A.

Regulatory Authorities

Portugal: Banco Espírito Santo de Investimento, S.A. is regulated by the Comissão do Mercado de Valores Mobiliários (the Portuguese Securities Market Authority); Spain: the branch in Madrid is regulated by the Comisión Nacional del Mercado de Valores (the Spanish Securities Market Authority); Poland: the branch in Warsaw is regulated by the Komisja Nadzoru Finansowego (the Polish Financial Supervision Authority); Brazil: BES Securities do Brasil, S.A. - Corretora de Câmbio e Valores Mobiliários is regulated by the Comissão de Valores Mobiliários (the Brazilian Securities Market Authority); United Kingdom: Execution Noble Limited is authorised and regulated by the Financial Conduct Authority; India: Espirito Santo Securities India Private Limited is regulated by the Securities and Exchange Board of India.

NOT FOR DISTRIBUTION TO ANY US PERSON OR TO ANY PERSON OR ADDRESS IN THE UNITED STATES OF AMERICA